GRIN3A

VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has signed a Letter of Intent (“LOI”) with Seyltx Inc. (“Seyltx”), a privately owned U.S. based drug development company, to acquire Algernon’s NP-120 (“Ifenprodil”) research program for USD $2M cash and a 20% common share equity position in Seyltx. The transaction is subject to certain conditions including, inter alia, Seyltx financing and the negotiation and execution of a definitive agreement, which is expected to occur within the next 90 days. Seyltx plans to conduct an Ifenprodil Phase 2b chronic cough study as soon as possible. As stated in the LOI, Algernon’s clinical management team will be available to provide support, oversight and management of the study. Ifenprodil is an N-methyl-D-aspartate (“NMDA”) receptor antagonist specifically targeting the NMDA type subunit 2B (GluN2B), which prevents glutamate signaling. Ifenprodil is Algernon’s lead research program and represents a novel first-in-class potential treatment for chronic cough. It is thought to interfere with central signalling in the brain, suppressing the urge to cough. “We are very pleased to have signed this LOI with Seyltx,” said Christopher J. Moreau, Algernon’s Chief Executive Officer. “With the U.S. FDA advisory panel recently voting 12 – 1 against approving Merck’s chronic cough drug candidate gefapixant, citing a lack of efficacy, it is very important to continue moving Ifenprodil forward as a potential global treatment of chronic cough.” Algernon’s Phase 2a Study Data Algernon’s decision to advance to a Phase 2b cough study was based on positive data previously reported from the Company’s proof of concept Phase 2a study of idiopathic pulmonary fibrosis (“IPF”) and chronic cough, where Ifenprodil showed a significant reduction in cough count. Patients with IPF are usually excluded from trials in refractory chronic cough (“RCC”), and cough in this population is regarded as extremely difficult to treat. Key Data: The geometric mean 24-hour cough counts were reduced by 32.0% at 4 weeks(p = 0.023) and 39.5% at 12 weeks (p = 0.001) compared to baselineThe geometric mean awake cough counts were reduced by 30.2% at 4 weeks(p = 0.038) and 37.4% at 12 weeks (p = 0.002) compared to baselineAlgernon previously announced on January 14, 2022, that it had received positive feedback from the U.S. Food and Drug Administration at its pre-Investigational New Drug (pre-IND) meeting for its investigation of Ifenprodil solely for the treatment of chronic cough. About Chronic Cough Chronic cough is defined as a cough lasting for more than eight weeks in duration and in the United States cough continues to be one of the most common reasons that adults consult medical doctors. Some cases of chronic cough are so debilitating that quality of life is severely impacted leading to depression, anxiety, urinary incontinence, dysphonia, sleep interruption, vomiting, and even rib fractures further adding to the decay in socio-familial dynamics. Chronic cough is believed to be the result of a hypersensitivity of the cough reflex within the neuronal circuitry that governs the urge to cough, wherein one or more aspects that regulate cough are over-active to stimulus, triggering a cough at abnormal levels. Trials of cough suppressants (“Antitussives”) have shown differences in response that may reflect differing pathological processes driving cough in different patients. Experimental Antitussives (like gefapixant and camlipixant) often only engage a single receptor, while the overall cough response is governed by multiple receptors triggered by a large variety of stimuli. A compound acting centrally in the brain, like ifenprodil, where all peripheral messages are sent and coordinated, may achieve a better outcome than what has been achieved by others in clinical trials. Chronic Cough Market According to Data Bridge Market Research analyses, the global chronic cough market was valued at USD $6.15B in 2021 and is projected to grow up to USD $11.38B by 2029. Merck & Co. obtained the rights to gefapixant, a P2X3 receptor antagonist, as the lead asset in the acquisition of Afferent Pharmaceuticals in 2016. At the time, gefapixant had interim data from a Phase 2b study in RCC. The deal was worth up to USD $1.25 billion. Bellus Health, which was advancing camlipixant, its own novel P2X3 receptor antagonist, closed a deal on June 16, 2023 with GSK plc which bought all the outstanding shares in Bellus for USD $14.75 per share in cash with a total deal value estimated at USD $2 billion, confirming the need for better therapies for chronic cough. About NP-120 (Ifenprodil) NP-120 selectively inhibits GluN2B receptors which diminish excitability of neurons and prevent the relaying of information along neuronal circuitry, including the cough reflex. NP-120 may also inhibit the neuroplastic enhancement of central and peripheral cough response neurons. About Seyltx Inc. Seyltx is a U.S.-based Delaware C-corporation focused on rapidly accelerating development of therapeutics that have established human safety and efficacy data. Seyltx is addressing underserved medical conditions that affect significant portions of the global population by selectively modulating neuronal receptors in the central nervous system that control pulmonary diseases. About Algernon Pharmaceuticals Inc. Algernon Pharmaceuticals is a Canadian clinical stage drug development company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals has active research programs for IPF with chronic cough, and chronic kidney disease, and is the parent company of a newly created private subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury. CONTACT INFORMATION Christopher J. MoreauCEOAlgernon Pharmaceuticals Inc.604.398.4175 ext 701 info@algernonpharmaceuticals.cominvestors@algernonpharmaceuticals.comwww.algernonpharmaceuticals.com Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024 Completing enrollment of the originally-targeted 70 patients in the Phase 2b/3 trial of NRX-101 in Treatment Resistant Bipolar Depression; enrollment to continue through November to increase study power; last patient visit expected in January. Data expected to be released shortly thereafter Opened the Investigational New Drug application (IND) with Food and Drug Administration (FDA) to treat chronic pain with NRX-101. Awaiting results of 200-person DOD-funded trial in treatment of chronic pain with D-cycloserine (DCS) from Northwestern University in the near term Received data from randomized, controlled trials demonstrating safety and efficacy of IV ketamine in treating suicidal depression, and established manufacturing partnership to enable filing of a New Drug Application (NDA) for what would be the first FDA-approved presentation of IV ketamine for this purpose in 1Q24. Planning a newly capitalized, publicly traded, ketamine-focused entity that will be owned by NRx, current NRx shareholders, and new investors; Term Sheet received from prospective anchor investor Submitted an IND application with FDA to treat complicated Urinary Tract Infection (cUTI) with NRX-101; Qualified Infectious Disease Product (QIDP) request response expected around year-end 2023. Management to address evidence of naked shorting of NRx securities Management to host a conference call tomorrow, November 14, 2023, at 4:30 PM ET RADNOR, Pa., Nov. 13, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended September 30, 2023 and provided a business update. Given the volume of information discussed this quarter, we have issued this release in advance of our conference call to allow investors additional time to review. "The third quarter represents a potential turning point for our company, as we are approaching our clinical trial enrollment goals for our partnered foundation product NRX-101, while opening new clinical initiatives in chronic pain, urinary tract infection, and NRX-100 for suicidal depression," said Stephen Willard, J.D., Chief Executive Officer and Director of NRx Pharmaceuticals. "We have four upcoming milestones: in our core clinical trial of NRX-101, in the Department of Defense (DOD) -funded clinical trial of DCS for chronic pain, in our program to open an IND and secure QIDP classification for NRX-101 in cUTI, and in our program to seek New Drug Approval for NRX-100 (intravenous ketamine) and establish that drug in a freshly-capitalized company. Achieving any one of those milestones has the potential to unlock substantial shareholder value, while success on more than one front has the potential to unlock exponential growth. "I am incredibly proud of our team, our collaborators & partners, and most of all the patients who have made such important contributions to these efforts. All of us at NRx are deeply grateful to the many shareholders who have reached out to us, encouraged us, and supported us during a period of immense challenge in the biotechnology market. Together, we are pursuing NRx's goal of bringing hope to life on a daily basis." Third Quarter Clinical, Regulatory and Corporate Highlights Development of NRX-101 for Treatment-Resistant Bipolar Depression (TRBD) The Company announces today that it is near completion of enrollment of the originally-targeted 70 participants in the Phase 2b/3 trial of NRX-101 in TRBD; enrollment will continue through November to increase study power. We expect top-line data from this cohort of patients shortly after the last patient visit. The target population is based on the Company's January 2023 meeting with the FDA in which the Company was guided to expand its intended use of NRX-101 from the original population of patients with acute suicidality who might be treated in the hospital environment to the broader population of patients with subacute suicidal ideation (now described by the Company as Treatment-Resistant Bipolar Depression) who are treated in the outpatient setting. Based on the guidance of the FDA and the Company's completion of manufacturing for phase 3/commercial stage investigational product, the Company upgraded the ongoing clinical trial to a phase 2b/3 trial, the results of which have the potential to be used for registrational filings. The data integrity standard identified last quarter (95% agreement between site raters and central raters) has been achieved across the newly-enrolled cohort of patients. In April 2023, the Company contracted with 1nHealth to initiate a recruitment campaign that may cover up to 45 states in the U.S. to recruit sufficient participants for this enlarged trial. The Company has similarly broadened its relationship with Science 37, a contract research organization that conducts decentralized clinical trials, to enroll participants identified by the 1nHealth recruitment initiative and randomize them to be treated within the broadened clinical trial. 1nHealth has additionally engaged "The Mighty," a voice-of-the-patient organization with national reach to publicize the clinical trial to the 800,000+ subscribers who have indicated a focus on bipolar depression and suicidality. The Company has completed manufacture of all clinical supplies required for its ongoing clinical trials. This initiative is expected to yield stability data sufficient to support a shelf life in excess of two years at time of potential drug launch (should the clinical trials be successful). The completion of this manufacturing milestone may allow the Company to decrease ongoing expenditure associated with manufacturing and development of chemical manufacturing controls. Product stability work has continued to support the targeted two-year shelf life at potential drug launch. During Q3, the Company has solidified its working relationship with Alvogen and begun working in unison to plan the final development and commercialization of NRX-101. As previously announced, a successful readout from this trial and FDA interaction will trigger a $10 million milestone payment from Alvogen together with transfer of future development costs to our partner. Based on milestones achieved during this quarter, the NRX-101 project is on track for completion of a pivotal trial in coordination with a commercial stage partner in less than two years from its re-initiation in March 2022 at the tail of the COVID pandemic to its projected readout. This includes the time required to complete transfer of manufacturing to the US and to validate a full chemistry, manufacturing and controls (CMC) and stability program with the FDA. NRX-101 for Treatment of Chronic Pain: The Company has previously detailed the scientific basis for treatment of chronic pain with DCS as outlined in a 2016 scientific paper published by Schnitzer, et. al. and in the White Paper posted by the Company's Scientific Leadership (Sappko, et. al.). In the second quarter, the Company licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain. Chronic pain affects more than 50 million American adults, compared to the approximately 3 million who report thoughts of suicide on an annual basis. There has been no new non-opioid class of drugs to treat nociceptive pain in the past two decades and NRX-101 has the potential to be the first N-methyl-D-aspartate (NMDA)-antagonist drug to seek approval for this indication. Today, ketamine is used off label to treat nociceptive pain, despite its clear limitations (addiction, neurotoxicity, hallucination, and the need for IV administration.) The Company awaits results of a 200-person randomized prospective trial funded by the US DOD (NCT 03535688) in which patients with chronic pain were randomly assigned to DCS 400mg/day vs. placebo. The investigators have identified primary completion of this trial as occurring in November 2023, with top-line results. Should these results support efficacy of DCS in the treatment of chronic low back pain, they are expected to provide a Breakthrough Therapy path towards treatment of chronic pain with DCS and DCS-containing medicines. Today, the Company is announcing that it has submitted NRX-101 for consideration by the multibillion dollar HEAL initiative (HEAL) and its national consortium of clinical trial sites (EPPICNET). This initiative was funded by the US Congress to test innovative non-opioid medicines for Chronic Pain. We believe that NRX-101 represents the first NMDA-targeted non-addictive medicine to be presented to this program. Should the DOD-funded trial yield encouraging data, the Company anticipates that non-dilutive sources of capital will be available, given the national focus on the opioid crisis. Progress in treating chronic pain with NRX-101 may open a far larger market for NRX-101 than the originally-targeted psychiatry indications. Progress on NRX-100 (ketamine) for treating acute suicidality. When NRx met with the FDA in January 2023, the agency strongly encouraged the Company to develop NRX-100 (ketamine) as a labeled drug, rather than rely on prior stabilization of suicidality and depression achieved via the common clinical practice of infusing generic ketamine compounded in licensed pharmacies. Shortly thereafter, the FDA issued the first of two advisory letters warning physicians against using compounded forms of ketamine and began a program of rigorous inspections of such pharmacies. Although there was once an expectation that intranasal administration of ketamine would be effective in treating suicidality, the attempts to demonstrate the clinical efficacy of nasal racemic ketamine for acute suicidality have not succeeded. Accordingly, in Q3 the Company finalized a scientific collaboration with Prof. Marion Leboyer of Paris, France and Prof. Mocrane Abbar of Lyon, France in order to incorporate the results of a 156-person inpatient trial of intravenous ketamine vs. placebo for the stabilization of patients admitted for acute suicidality (the KETIS trial). The findings of the trial demonstrate a statistically significant reduction in both suicidality (the primary endpoint) and depression (the secondary endpoint) among patients treated with intravenous ketamine compared to those treated with placebo. (Link) The patient-level deidentified data have now been received by the Company and are being assembled in the electronic format required by the FDA. The Company is now in the process of negotiating access to similar patient-level data from an National Institutes of Health (NIH)-funded US-based clinical trial the findings of which confirm the KETIS trial. The Company believes that these multicenter, randomized prospective trials encompassing more than 240 participants, combined with randomized, prospective data on more than 200 US patients when submitted for review at a patient level could be sufficient to demonstrate preliminary safety and efficacy of intravenous ketamine in acutely suicidal patients. Data are expected to be transmitted to FDA by the end of 4Q23. Submission of an NDA for the use of IV Ketamine is dependent upon submission of a manufacturing file documenting the manufacture of a presentation of ketamine suitable for single-patient use in the treatment of suicidal depression. In November 2023, the Company announced the signing of a development and manufacturing agreement with Nephron Pharmaceuticals, Inc. (West Columbia, SC) to develop a single patient presentation of ketamine. This formulation is expected to overcome some of the formulation deficiencies of existing forms of ketamine (developed for anesthesia) and is expected to have diversion-resistant and tamper-resistant features. The Company believes that this latter aspect is important because of the well-known uses of ketamine as a drug of abuse and as a vehicle for date rape. DOJ Date Rape Drugs The Company's current timeline projects submission of a New Drug Application for ketamine in the first quarter of 2024 with a targeted PDUFA date in Q4 2024. Nephron has considerable experience in the manufacture of ketamine products and, therefore, the Company anticipates that two-year shelf stability at launch may be achieved with six months of real-time accelerated stability. Establishment of a ketamine-focused spinoff company The Company does not anticipate funding this initiative with its core NRx assets and today advised investors of its plan to establish a ketamine-focused spinoff company that would potentially provide current and new investors with both capital appreciation and a royalty stream. A term sheet for up to $30 million in anchor financing for a new public entity has been presented to management by a capable investor and a structure whereby a portion of the equity in the ketamine asset will be allocated to existing shareholders. This proposal will be discussed at the upcoming annual meeting of shareholders. There is an acute public health need for a safely manufactured, divergent-resistant form of ketamine, particularly in light of drug shortages caused by newly (and appropriately) rigorous FDA manufacturing standards. NRx anticipates a near-term potential address this public health need by year end 2024. Treatment of Urinary Tract Infection (UTI) and Urosepsis: Although treatment of UTI is quite different from use of NRX-101 to treat Central Nervous System disorders, D-cycloserine was originally developed as an antibiotic because of its role in disrupting the cell wall of certain pathogens. This is true of a number of drugs used in psychiatry today. D-cycloserine fell out of favor as an antibiotic in the 1970s because of the CNS effects caused by its NMDA-blocking properties and because of the widespread availability of effective first and second-generation antibiotics. However, DCS is unique in its near-100% excretion in the urine and the ability to achieve high urinary tract levels of DCS with oral administration. The Company's clinical experience in psychiatry suggests that the lurasidone component of NRX-101 blocks unwanted CNS effects and unlocks the potential to treat antibiotic-resistant urinary tract infections with decreased propensity to cause unwanted CNS effects. In recent years, increased antibiotic resistance to common pathogens that cause urinary tract infections and urosepsis (i.e., sepsis originating in the urinary tract) has resulted in a marked increase in cUTI, hospitalization, and death from urosepsis. The US Center for Disease Control and Prevention reports that more than 1.7 million Americans contract sepsis each year, of whom at least 350,000 die during their hospitalization or are discharged to hospice (CDC Sepsis Ref.). In 2015 DCS was demonstrated to be effective against pathogens that are increasingly resistant to first- and second-line antibiotics. During Q3 2023, NRx tested NRX-101 and its components against resistant pathogens that appear on the Congressionally-mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter – thereby appearing to meet the requirements of the QIDP program. Qualification for QIDP affords a sponsor five years of additional market exclusivity from FDA, regardless of patent status, together with Fast Track Designation and Priority Review. The Company believes that NRX-101 as an oral medication has the potential to demonstrate benefit in patients who would otherwise require intravenous third and fourth generation antibiotics. There are approximately 3 million patients per year who contract cUTI in the US annually (Lodise, et. al.). Additionally, should NRX-101 succeed in clinical trials, the Company will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity. Based on the in vitro study performed at CRL, the Company has submitted an Investigational New Drug application, requesting QIDP, Fast Track, and Priority Review designation. FDA approval of this IND is expected by year-end 2023. As with the NRX-100 development project, the Company does not anticipate funding this initiative with core NRx assets and is exploring structures for a new entity that would provide current and new investors with both capital appreciation and a royalty stream. Should the Company succeed in serving 10% of the cUTI market, the Company believes that the revenue from NRX-101 has the potential to hundreds of million annually, based on 3 million cases per year (Lodise, et. al.) in the US and potential pricing of over $3,500/course of therapy. Cash runway and financing The Company continues to believe cash on hand is sufficient to fund operations through potential delivery of the upcoming milestones described herein. As discussed, funding of ketamine-related and UTI-related initiatives is anticipated under new entities with alternative financing. Additional financing plans to be discussed at the upcoming meeting of shareholders. Share price suppression associated with Naked Shorting Shareholders and others have repeatedly noted that the Company's share price appears to be adversely affected by short sales of stock that frequently accompany positive news. While covered short sales (i.e. those sales that are accompanied by borrowing of an existing share of stock) is legal, "naked" shorting, without an underlying borrowed share, is not. A recent Federal Court decision holds brokerages liable for damages to companies associated with persistent naked short positions. In Q3, the Company contracted with ShareIntel, Inc. to examine disparities between NRx stock positions as reported by brokerages and NRx shares reported by DTC, the electronic clearinghouse for the Nasdaq exchange. The Company is today announcing that persistent disparities of approximately 1 million to 1.5 million shares were identified. The Company's has now instructed its counsel to initiate outreach to the compliance departments of the identified brokerages, demanding that all uncovered short positions in the Company's stock be closed via a forced delivery of shares. The Company has been advised by counsel that this action has resulted in share appreciation when implemented by other issuers of Nasdaq stock. Financial Results for the Second Quarter Ended September 30, 2023 For the three months ended September 30, 2023, NRx Pharmaceuticals recorded $3.3 million of research and development expenses compared to $4.1 million for the three months ended September 30, 2022. The decrease of $0.8 million is related primarily to a decrease of $0.5 million in clinical trials and development expenses related to the NRX-101 program for Suicidal Treatment-Resistant Bipolar Depression partially offset by a increase in various other costs. For the nine months ended September 30, 2023, NRx Pharmaceuticals recorded $10.8 million of research and development expenses compared to $12.6 million for the nine months ended September 30, 2022. The decrease of $1.8 is related primarily to a decrease of $1.0 million in clinical trials and development expenses, $0.9 million related to fees paid to regulatory and process development consultants, $0.2 million in stock-based compensation, partially offset by an increase in various other costs. For the three months ended September 30, 2023, NRx Pharmaceuticals recorded $2.5 million of general and administrative expenses compared to $5.0 million for the three months ended September 30, 2022. The decrease related primarily of a decrease of $1.3 million in insurance expenses, $0.9 million in employee expenses, $0.2 million in stock-based compensation expense, $0.3 million in legal, professional and accounting fees partially offset by an increase in various other costs. For the nine months ended September 30, 2023, NRx Pharmaceuticals recorded $12.3 million of general and administrative expenses compared to $21.9 million for the nine months ended September 30, 2022. The decrease of $9.5 million is related primarily to a decrease of $4.9 million in legal, professional and accounting fees, $2.8 million in insurance expenses, $1.1 million in stock-based compensation expense, $0.5 million in consultant fees, $0.4 million in employee expenses, partially offset by an increase in various other costs. For the three months and ended September 30, 2023, NRx Pharmaceuticals recorded $6.1 million in net loss compared to $9.1 million for the quarter ended September 30, 2022. For the nine months and ended September 30, 2023, NRx Pharmaceuticals recorded $25.8 million in net loss compared to $29.5 million for the quarter ended September 30, 2022. As of September 30, 2023, we had $8.9 million in cash and cash equivalents. The company continues to believe cash on hand is sufficient to fund operations through potential delivery of the upcoming milestones described herein. Additionally, we are evaluating operational efficiencies to extend this runway. Conference Call and Webcast Details A live webcast of the conference call will be available on the Company's website tomorrow at 4:30 p.m. ET, at . An archive of the webcast will be available on the Company's website for 30 days. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1 (833) 630-1956 or internationally +1 (412) 317-1837. About NRX-101 NRX-101, a fixed dose combination of D-cycloserine and lurasidone, has been granted Fast Track Designation, Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support from the FDA for Bipolar Depression with Suicidality. NRX-101 is further being developed for chronic pain and PTSD. Up to 50% of individuals with bipolar disorder attempt suicide over their lifetime, and estimates indicate that up to 20% may die by suicide. The only FDA-approved treatment for patients with suicidal bipolar depression remains electroconvulsive therapy. Conventional antidepressants can increase the risk of suicide in certain patients; hence their labels contain a warning to that effect. NRX-101 is a patented, oral, fixed dose combination of D-cycloserine and lurasidone, neither of which has shown addiction potential in preclinical models. Based on the results of the STABIL-B trial, NRX-101 received Breakthrough Therapy Designation from the FDA for the treatment of patients with severe bipolar depression and acute suicidality after initial stabilization with ketamine or other effective therapy. NRX-101 is one of the first oral antidepressants currently in late-stage clinical studies targeting the NMDA-receptor in the brain, which represents potentially a key new mechanism to treat depression with and without suicidality, as well as chronic pain, PTSD and other indications. About NRx Pharmaceuticals NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain. NRx has recently announced plans to submit a New Drug Application for ketamine in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. Cautionary Note Regarding Forward-Looking Statements This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management. The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above. SOURCE NRx Pharma